Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia

Am J Hematol. 2015 Jun;90(6):561-3. doi: 10.1002/ajh.23969. Epub 2015 May 10.

Authors

Mary E Sehl¹, Theresa M Gruber¹, Justin P McWilliams², Victor J Marder¹

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
² Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, California.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Aged
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Bevacizumab
Gastrointestinal Hemorrhage / blood
Gastrointestinal Hemorrhage / drug therapy*
Humans
Male
Telangiectasia, Hereditary Hemorrhagic / blood
Telangiectasia, Hereditary Hemorrhagic / drug therapy*

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Bevacizumab

Grants and funding